Skip to main content
    C

    Cellectis SA (CLLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.02 (-1.34%)

    Market Cap: $110.81M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -1.71%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.23 - $-0.15
    5 analysts
    EPS Revisions
    5
    0
    7d
    5
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.22+12.9%
    60d ago$-0.22+12.9%
    30d ago$-0.20+3.6%
    7d ago$-0.20+3.6%
    Current$-0.20
    Revenue Consensus
    $14M
    Range$9M - $17M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.47 - $0.19
    5 analysts
    Revenue Consensus
    $17M
    Range$-2481830 - $34M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Aug 6
    		$-0.22$-0.25+12.00%Beat+0.0%
    Mar 26
    Reported May 11
    		$-0.18$-0.26+30.77%Beat-5.9%
    Dec 25
    Reported Mar 19
    		$-0.24$-0.29+18.59%Beat-50.0%
    Sep 25
    Reported Nov 7
    		$0.02N/A+120.00%Beat+109.1%
    Jun 25
    Reported Aug 4
    		$-0.22$-0.15-46.67%Miss+18.5%
    Mar 25
    Reported May 12
    		$-0.17$-0.16-6.25%Miss-21.4%
    Dec 24
    Reported Mar 13
    		$-0.16$-0.09-77.78%Miss+77.1%
    Sep 24
    Reported Nov 4
    		$-0.22$-0.24+8.33%Beat+40.5%
    Jun 24
    Reported Aug 6
    		$-0.27$-0.27+0.00%Beat-80.0%
    Mar 24
    Reported Apr 29
    		$-0.14$-0.27+48.15%Beat+74.5%
    Dec 23
    Reported Mar 13
    		$-0.70$-0.22-218.18%Miss-18.6%
    Sep 23
    Reported Nov 6
    		$-0.37$-0.36-2.78%Miss+41.3%
    Jun 23
    Reported Aug 3
    		$-0.15N/A+55.88%Beat+64.3%
    Mar 23
    Reported May 4
    		$-0.55$-0.42-30.95%Miss+21.4%
    Dec 22
    Reported Mar 8
    		$-0.59$-0.71+16.90%Beat-7.3%
    Sep 22
    Reported Nov 3
    		$-0.63$-0.21-200.00%Miss+23.2%
    Jun 22
    Reported Aug 4
    		$-0.42$-0.57+26.32%Beat+52.3%
    Mar 22
    Reported May 12
    		$-0.70$-0.66-6.06%Miss-150.0%
    Dec 21
    Reported Mar 3
    		$-0.55$-0.92+40.22%Beat+42.1%
    Sep 21
    Reported Nov 4
    		$-0.82$-0.75-9.33%Miss-15.5%
    Jun 21
    Reported Aug 5
    		$-0.88$-0.65-35.38%Miss-15.8%
    Mar 21
    Reported May 6
    		$-0.28N/A+61.11%Beat-159.6%
    Dec 20
    Reported Mar 4
    		$-0.95$-0.78-21.79%Miss-8.0%
    Sep 20
    Reported Nov 5
    		$-0.71$-0.50-42.00%Miss-208.7%
    Jun 20
    Reported Aug 5
    		$-0.76$-0.74-2.70%Miss-16.9%
    Mar 20
    Reported May 6
    		$0.47$-0.65+172.31%Beat+280.8%
    Dec 19
    Reported Mar 4
    		$-0.88$-0.73-20.55%Miss-66.0%
    Sep 19
    Reported Nov 6
    		$-0.23$-0.42+45.24%Beat+36.1%
    Jun 19
    Reported Aug 6
    		$-0.65$-0.36-80.56%Miss-2266.7%
    Mar 19
    Reported May 7
    		$-0.26$-0.32+18.75%Beat+33.3%
    Dec 18
    Reported Mar 11
    		$-0.53$-0.71+25.35%Beat+30.3%
    Sep 18
    Reported Nov 13
    		$-0.36$-0.31-16.13%Miss+2.7%
    Jun 18
    Reported Aug 1
    		$0.03N/A+108.82%Beat+107.0%
    Mar 18
    Reported May 7
    		$-0.39$-0.38-2.63%Miss-129.4%
    Dec 17
    Reported Mar 12
    		$-0.76$-0.72-5.56%Miss-100.0%
    Sep 17
    Reported Nov 13
    		$-0.37$-0.34-8.82%Miss-
    Jun 17
    Reported Aug 2
    		$-0.43$-0.22-95.45%Miss-
    Mar 17
    Reported May 9
    		$-0.17N/A+54.05%Beat-
    Dec 16
    Reported Mar 6
    		$-0.38$-0.38+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.78EV/EBITDAN/A
    Price/FCF-2.52xFCF Yield-39.62%
    Profitability
    Profit Margin-102.30%Operating Margin-340.70%
    ROE-94.50%ROIC-74.14%
    Financial Health
    Debt/Equity1.31xInterest Coverage-8.85x
    Current Ratio1.37xQuick Ratio1.37x
    Trading Statistics
    Beta2.91Avg Volume127.03K
    52-Week High$5.4552-Week Low$1.09

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.26
    SMA 20$1.37
    SMA 50$2.32
    SMA 200$3.26
    EMA 10$1.25
    EMA 20$1.48
    EMA 50$2.04
    EMA 200$2.88

    MACD

    Line: -0.33Signal: -0.35Hist: 0.02

    ADX

    ADX: 53.2+DI: 9.2-DI: 47.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.28

    Bollinger Bands

    Upper Band$1.67
    Lower Band$1.07
    %B Position4329%(Upper)
    Band Width0.05

    RSI (14-Day)

    Oversold
    21.5

    Momentum Oscillators

    Stoch %K4.2
    Stoch %D5.8
    Williams %R-96.6
    ROC (10d)-21.1%
    Momentum-0.29
    CCI (20d)-148.1
    MFI (14d)32.8

    Volatility Measures

    ATR (14d)$0.12(11.3%)
    StdDev (20d)0.15
    Hist Vol62.3%(High)

    Volume Flow

    VWAP$1.11
    OBV3.3M
    AD Line-2.6M
    CMF (20d)-0.152

    Volume Metrics

    Avg Vol (20d)88.7K
    Vol Ratio1.1x
    VWMA (20d)$1.37

    Pivot Points

    R3$1.20
    R2$1.17
    R1$1.15
    Pivot Point$1.12
    S1$1.10
    S2$1.07
    S3$1.05

    Advanced Oscillators

    TSI-53.42
    Ultimate Osc28.3
    KST-433.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.22M$5.80M$10.40M$35.17M$16.73M$10.65M$12.72M$16.20M$8.06M$4.53M$285,392$155,000
    Cost of Revenue$4.41M$4.55M$3.00M$2.36M$2.42M$2.02M$2.52M$2.79M$1.53M$2.35M$5.39M$181,000
    Gross Profit$815,868$1.25M$7.40M$32.81M$14.30M$8.64M$10.20M$13.41M$6.53M$2.18M$-5,102,783$-26,000
    Operating Expenses$26.27M$28.35M$24.75M$24.77M$23.89M$22.82M$20.88M$24.18M$23.74M$23.08M$25.91M$20.64M
    R&D$20.89M$23.09M$24.44M$24.07M$23.08M$21.93M$20.87M$23.83M$23.52M$22.32M$25.74M$19.07M
    SG&A$3.03M$2.91M$1.50M$2.48M$2.29M$2.33M$934,000$2.01M$2.35M$2.37M$4.67M$3.23M
    Operating Income$-25,450,716$-27,099,145$-17,351,000$8.04M$-9,587,000$-14,179,000$-10,680,000$-10,769,000$-17,211,000$-20,894,000$-31,007,983$-20,671,000
    Interest Income$1.55M$1.84M$2.08M$2.31M$2.19M$2.91M$3.57M$3.02M$2.77M$1.92M$1.45M$723,000
    Interest Expense$2.01M$2.27M$2.03M$2.11M$2.08M$1.91M$1.71M$2.15M$1.83M$1.79M$17.71M$1.62M
    Income Before Tax$-23,436,509$-19,560,843$-26,742,000$589,000$-23,736,000$-18,127,000$6.44M$-23,117,000$-25,463,000$5.38M$-64,906,200$-17,376,000
    Income Tax Expense$-1,647,715$-1,731,270$-423,000$0$-1,000$1,000$514,000$-59,000$-193,000$-262,000$-746,256$106,000
    Net Income$-21,788,793$-17,829,573$-26,318,000$589,000$-23,735,000$-18,128,000$5.92M$-23,056,000$-25,270,000$5.64M$-43,224,411$-17,482,000
    EBITDA$-21,038,716$-22,547,661$-19,605,000$7.71M$-16,664,000$-11,285,000$14.17M$-16,475,000$-18,900,000$11.74M$-25,825,983$-11,400,000
    EBIT$-25,450,716$-27,099,145$-24,708,000$2.70M$-21,681,000$-16,216,000$8.35M$-21,195,000$-23,628,000$7.17M$-31,007,983$-15,866,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLLS

    News

    Securities Fraud Investigation Into Cellectis S.A. (CLLS)

    Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Cellectis S.A. (CLLS) on behalf of investors who lost money. The investigation follows Cellectis's announcement on September 14...

    GlobeNewswire•10/15/26•Bearish

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

    Pomerantz LLP is investigating claims on behalf of investors of Cellectis S.A. (NASDAQ: CLLS) following a significant drop in its American Depositary Receipt (ADR) price. This investigation comes after Cellectis...

    PR Newswire•10/15/26•Bearish

    Securities Fraud Investigation Into Cellectis S.A. (CLLS)

    The Law Offices of Frank R. Cruz is investigating Cellectis S.A. (CLLS) for possible federal securities law violations after the company announced it would discontinue certain CAR-T cell therapies due to limited cash...

    GlobeNewswire•10/14/26•Bearish

    Law firm probes Cellectis over stock drop after halting CAR-T therapy development

    Pomerantz LLP is investigating Cellectis S.A. for potential securities fraud after the company's decision to discontinue CAR-T cell therapies and focus on in vivo gene editing caused its ADR price to fall by nearly 41%....

    Pluang•10/13/26•Bearish

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

    Pomerantz LLP is investigating potential claims on behalf of investors of Cellectis S.A. (NASDAQ: CLLS) regarding alleged securities fraud or unlawful business practices. This investigation follows Cellectis's...

    PR Newswire•10/8/26•Bearish

    CLLS Valuation and Fair Value

    P/E
    -1.8x
    P/FCF
    -2.5x
    PEG
    0.0x
    P/B
    2.7x
    See GNG's fair value

    CLLS Profitability: Margins, ROIC and FCF

    Gross margin
    74.7%
    Operating margin
    -340.7%
    Net margin
    -102.3%
    ROIC
    -74.1%
    ROE
    -94.5%
    FCF margin
    -77.9%
    FCF yield
    -39.6%

    CLLS Competitors

    CompanyTicker
    vTv Therapeutics IncVTVT
    Foghorn Therapeutics IncFHTX
    NRX Pharmaceuticals IncNRXP
    Tonix Pharmaceuticals Holding CorpTNXP
    TuHURA Biosciences IncHURA
    LENZ Therapeutics IncLENZ
    Minerva Neurosciences IncNERV
    enGene Holdings Inc. Common StockENGN

    Sector: Healthcare

    CLLS Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    2
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    CLLS Bull Case vs Bear Case

    Bull case

    • 80.0% of CLLS's analyst ratings are Buy or Strong Buy.

    Bear case

    • CLLS has a -102.3% net profit margin.
    • CLLS's quarterly revenue changed -62.1% year over year.

    CLLS Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    7.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    5 up, 0 down

    Frequently Asked Questions About CLLS

    Does CLLS pay dividends?

    Cellectis SA (CLLS) does not currently pay a regular dividend.

    What is CLLS's market cap?

    Cellectis SA (CLLS) has a market capitalization of $110.81M with a current stock price of $1.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In